Successfully reported this slideshow.
Asia Investor Meeting
30 November 2007
J W Marriott
Valid as of November 30, 2007
Introduction
Pfizer Overview
Amal Naj
SVP, WW Investor Development & Strategy
Asia Investor Meeting
Valid as of November 3...
3
Forward-Looking Statement and
Non-GAAP Financial Information
Our discussions during this meeting will include forward-lo...
4
Welcome to Pfizer
We Are the WorldWe Are the World’’s Leading Healthcare Company with:s Leading Healthcare Company with:...
5
Aricept
Cabaser
Dilantin
Geodon/Zeldox
Lyrica
Neurontin
Relpax
Xanax/Xanax XR
Zoloft
Aricept
Cabaser
Dilantin
Geodon/Zel...
6
Recently Launched Products
Launched in the U.S. since 2005 Valid as of November 30, 2007
7
Pharmaceutical Portfolio
By 2006 Sales
$200M+
$500M+
$1B+
$12B+
$2B+
CARDURACARDURA
Source: Pfizer Inc. 2006 Pfizer Annu...
8
HorsesHorses
Cats
Dogs
Cats
Dogs
Dairy Cattle
Beef Cattle
Swine
Dairy Cattle
Beef Cattle
Swine
Pfizer Animal HealthPfize...
9
Industry and Pfizer
Are Facing Many Challenges
Unprecedented Patent Expirations
Generic Competition
Pricing Pressures
Fe...
10
Immediate Priorities to Change
with the Industry
Maximize Our Near and Long-Term Revenues
Establish a Lower and More Fl...
11
TSRTSR
Focus on Total Shareholder Return
Cost
Management
Cost
Management
Revenue
Growth
Strategy
Revenue
Growth
Strateg...
12
$0.06 $0.06
$0.08
$0.09
$0.11
$0.13
$0.15
$0.17
$0.19
$0.24
$0.29
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 200...
13
Financial Highlights
($ Millions, Except Per-Share Amounts)($ Millions, Except Per-Share Amounts)
Results Impacted by L...
14
2007 Financial Guidance
3% to 5% Decline From 2006Lipitor RevenuesLipitor Revenues
$12.0 to $13.0 BillionCash Flows fro...
15
2008 Financial Guidance
1 See Slide 13 for definition.
2 At 2006 Exchange Rates
3 On Adjusted Income1
4 Represents prim...
16
Asian Countries Will Dominate the
Global Economy in the Future
Asia forecast to have 3 of 5 largest global economies by...
17
Pfizer Well Positioned &
Investing for Growth in Asia
Strategic Highlights include:
● 2005: Opened Shanghai Research Ce...
Martin Mackay
President,
Pfizer Global Research & Development
November 30, 2007
Pfizer Research &
Development
Asia Investo...
19
R&D Five Point Plan
Deliver the Phase II and Phase III
Portfolio
Prioritize our Portfolio to Deliver
the Most Value
Top...
20
R&D Footprint
CambridgeCambridge
TokyoTokyo
ShanghaiShanghaiNew YorkNew York
SingaporeSingapore
St. LouisSt. Louis
La J...
21
R&D Therapeutic Areas
GERD
Liver Fibrosis
IBD
GERD
Liver Fibrosis
IBD
Gastrointestinal
Indications
Gastrointestinal
Ind...
22
Global Reach & Unprecedented Scale
~400 projects in Discovery Research
~200 Development projects
~100 distinct new mole...
23
Expanding the Scope
A Leader in Innovation
*Currently under development
TherapyTherapyDiseaseDiseaseMechanismMechanism
...
24
Oncology Leader
Phase 1Phase 1
Phase 3Phase 3
Phase 2Phase 2
PreclinicalPreclinical
MarketMarket
Angiogenesis Inhibitor...
25
SutentSutent
AxitinibAxitinib
CPCP--675206675206
NSCLC, Breast,
and Colorectal
NSCLC, Breast,
and Colorectal
Thyroid an...
26
Examples of Our Rich Portfolio of
Phase 2 Candidates
CP-690550
CP-751871
PF-4383119
PF-3187207
PD-200390
CP-690550
CP-7...
27
Expanding the Scope of R&D
(interferon beta-1a) (dalteparin sodium injection)
(pegvisomant for
injection)
MCSF mAbMCSF ...
28
Expanding Science Outside Our Walls
Biotherapeutics & Bioinnovation Center
Bristol-Myers Squibb
● Apixiban
● WW collabo...
29
China R&D Center (CRDC)
Newest R&D facility
Located in the renowned
Zhangjiang High Tech Park,
Shanghai, China
Support ...
30
Clinical Research Unit – Singapore
One of three Pfizer Phase 1 Units
Relocated to state-of-the-art facility
in Raffles ...
31
DJ (Development Japan), Tokyo
Full capacity development
organization
Co-located with Pfizer Japan
Headquarters
385 staf...
32
Five Point Plan
Deliver the Phase II and Phase III
Portfolio
Prioritize our Portfolio to Deliver
the Most Value
Top-Tie...
Q&A Session
Asia Investor Meeting
Valid as of November 30, 2007
Upcoming SlideShare
Loading in …5
×

Asia Investor Meeting

685 views

Published on

  • Be the first to comment

  • Be the first to like this

Asia Investor Meeting

  1. 1. Asia Investor Meeting 30 November 2007 J W Marriott Valid as of November 30, 2007
  2. 2. Introduction Pfizer Overview Amal Naj SVP, WW Investor Development & Strategy Asia Investor Meeting Valid as of November 30, 2007
  3. 3. 3 Forward-Looking Statement and Non-GAAP Financial Information Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2006 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K. Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer’s Current Report on Form 8-K dated October 18, 2007 and Quarterly Report on Form 10-Q dated November 5, 2007. These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section. Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2006 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K. Also, the discussions during this meeting will include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in Pfizer’s Current Report on Form 8-K dated October 18, 2007 and Quarterly Report on Form 10-Q dated November 5, 2007. These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section. Valid as of November 30, 2007
  4. 4. 4 Welcome to Pfizer We Are the WorldWe Are the World’’s Leading Healthcare Company with:s Leading Healthcare Company with: A 157-year history originating in Brooklyn, NY Approximately $48 billion in annual sales in over 150 countries in 2006 About 90,000 colleagues worldwide Serves over 38 million patients worldwide The largest privately funded biomedical R&D organization – $7.6 billion in 2006 A 157-year history originating in Brooklyn, NY Approximately $48 billion in annual sales in over 150 countries in 2006 About 90,000 colleagues worldwide Serves over 38 million patients worldwide The largest privately funded biomedical R&D organization – $7.6 billion in 2006 Valid as of November 30, 2007
  5. 5. 5 Aricept Cabaser Dilantin Geodon/Zeldox Lyrica Neurontin Relpax Xanax/Xanax XR Zoloft Aricept Cabaser Dilantin Geodon/Zeldox Lyrica Neurontin Relpax Xanax/Xanax XR Zoloft Diflucan Selzentry/Celsentri Sulperazon Unasyn Vfend Viracept Zithromax/Zmax Zyvox Zyrtec/Zyrtec D Diflucan Selzentry/Celsentri Sulperazon Unasyn Vfend Viracept Zithromax/Zmax Zyvox Zyrtec/Zyrtec D Genotropin Somavert Genotropin Somavert Xalatan Macugen Xalatan Macugen EndocrineEndocrine OncologyOncology Infectious & Respiratory Disease Infectious & Respiratory Disease Cardiovascular/ Metabolic Cardiovascular/ Metabolic OphthalmologyOphthalmology 2007 Key Pharmaceutical Products by Therapeutic Area Central Nervous System Central Nervous System Arthritis & PainArthritis & Pain UrologyUrology Aromasin Camptosar Ellence/ Pharmorubicin Sutent Aromasin Camptosar Ellence/ Pharmorubicin Sutent Accupril/Accuretic Caduet Cardura/Cardura XL Chantix/Champix Glucotrol/Glucotrol XL Inspra Lipitor Norvasc/Istin Procardia/Procardia XL Tikosyn Accupril/Accuretic Caduet Cardura/Cardura XL Chantix/Champix Glucotrol/Glucotrol XL Inspra Lipitor Norvasc/Istin Procardia/Procardia XL Tikosyn Detrol/Detrol LA Viagra Detrol/Detrol LA Viagra Celebrex/CelebraCelebrex/Celebra Valid as of November 30, 2007
  6. 6. 6 Recently Launched Products Launched in the U.S. since 2005 Valid as of November 30, 2007
  7. 7. 7 Pharmaceutical Portfolio By 2006 Sales $200M+ $500M+ $1B+ $12B+ $2B+ CARDURACARDURA Source: Pfizer Inc. 2006 Pfizer Annual Report Valid as of November 30, 2007
  8. 8. 8 HorsesHorses Cats Dogs Cats Dogs Dairy Cattle Beef Cattle Swine Dairy Cattle Beef Cattle Swine Pfizer Animal HealthPfizer Animal Health Not Just Pharmaceuticals… Valid as of November 30, 2007
  9. 9. 9 Industry and Pfizer Are Facing Many Challenges Unprecedented Patent Expirations Generic Competition Pricing Pressures Fewer New Drug Approvals by the FDA Research and Development Productivity Unprecedented Patent Expirations Generic Competition Pricing Pressures Fewer New Drug Approvals by the FDA Research and Development Productivity Valid as of November 30, 2007
  10. 10. 10 Immediate Priorities to Change with the Industry Maximize Our Near and Long-Term Revenues Establish a Lower and More Flexible Cost Base Create Smaller, More Focused and More Accountable Operating Areas Engage More Productively with Customers, Patients, Physicians and Other Collaborators Make Pfizer a Great Place to Work Maximize Our Near and Long-Term Revenues Establish a Lower and More Flexible Cost Base Create Smaller, More Focused and More Accountable Operating Areas Engage More Productively with Customers, Patients, Physicians and Other Collaborators Make Pfizer a Great Place to Work Valid as of November 30, 2007
  11. 11. 11 TSRTSR Focus on Total Shareholder Return Cost Management Cost Management Revenue Growth Strategy Revenue Growth Strategy CultureCulture Capital Allocation Strategy Capital Allocation Strategy Valid as of November 30, 2007
  12. 12. 12 $0.06 $0.06 $0.08 $0.09 $0.11 $0.13 $0.15 $0.17 $0.19 $0.24 $0.29 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 (Quarterly Dividend per Share)(Quarterly Dividend per Share) Dividend Growth Strong Operating Cash Flow Has Supported Dividend Growth 18% CAGR Over Past Ten Years 40 Consecutive Years of Dividend Increases 21% Increase in 2007 Dividend Strong Dividend Yield Strong Operating Cash Flow Has Supported Dividend Growth 18% CAGR Over Past Ten Years 40 Consecutive Years of Dividend Increases 21% Increase in 2007 Dividend Strong Dividend Yield Amounts reflect stock splits in 1997 and 1999 Valid as of November 30, 2007
  13. 13. 13 Financial Highlights ($ Millions, Except Per-Share Amounts)($ Millions, Except Per-Share Amounts) Results Impacted by Loss of US Exclusivity forResults Impacted by Loss of US Exclusivity for 2 Key Products and Charges Related to Exubera2 Key Products and Charges Related to Exubera 1 Adjusted Income and its components and Adjusted Diluted EPS are defined as Reported Net Income and its components and Reported Diluted EPS, excluding Purchase Accounting Adjustments, Acquisition-Related Costs, Discontinued Operations, and Certain Significant Items. 3%1.631.687%0.540.58Adjusted Diluted EPS1 (2%)11,93511,7111%3,9223,963Adjusted Income1 (42%)1.350.78(76%)0.460.11Reported Diluted EPS (45%)9,8885,420(77%)3,362761Reported Net Income (1%)$35,768$35,548(2%)$12,280$11,990Reported Revenues ChangeChange2006200620072007ChangeChange2006200620072007 Nine Months (YTD)Nine Months (YTD)Third QuarterThird Quarter Valid as of November 30, 2007
  14. 14. 14 2007 Financial Guidance 3% to 5% Decline From 2006Lipitor RevenuesLipitor Revenues $12.0 to $13.0 BillionCash Flows from OperationsCash Flows from Operations 22.0%Effective Tax RateEffective Tax Rate44 $2.10 to $2.15Adjusted Diluted EPSAdjusted Diluted EPS11 $1.01 to $1.10Reported Diluted EPSReported Diluted EPS Approximately $7.5 BillionAdjusted R&D ExpensesAdjusted R&D Expenses11 Decrease of approx. $600 Million versus 2006 on a constant currency basis3 to approx. $15.1 Billion Adjusted SI&A ExpensesAdjusted SI&A Expenses11 Approximately 15.5%Adjusted Cost of SalesAdjusted Cost of Sales1,1, 22 $47.5 to $48.0 BillionRevenuesRevenues 1 See Slide 13 for definition. 2 As a Percentage of Revenues 3 At 2006 Exchange Rates 4 On Adjusted Income1 Valid as of November 30, 2007
  15. 15. 15 2008 Financial Guidance 1 See Slide 13 for definition. 2 At 2006 Exchange Rates 3 On Adjusted Income1 4 Represents primarily the total of Adjusted Cost of Sales1, Adjusted SI&A expenses1, and Adjusted R&D expenses1 $18.0 to $19.0 BillionCash Flows from OperationsCash Flows from Operations 22.0% to 22.5%Effective Tax RateEffective Tax Rate33 $2.31 to $2.45Adjusted Diluted EPSAdjusted Diluted EPS11 $1.75 to $1.93Reported Diluted EPSReported Diluted EPS Reduction of at least $1.5 to $2.0 Billion from 2006 on a constant currency basis2 Adjusted Total CostsAdjusted Total Costs44 $46.5 to $48.5 BillionRevenuesRevenues Valid as of November 30, 2007
  16. 16. 16 Asian Countries Will Dominate the Global Economy in the Future Asia forecast to have 3 of 5 largest global economies by 20171 Asia pharma market to reach ~$200 Billion by 20172 ~2.5 Billion lower-middle income patients currently underserved in Asia3 Asia forecast to have 3 of 5 largest global economies by 20171 Asia pharma market to reach ~$200 Billion by 20172 ~2.5 Billion lower-middle income patients currently underserved in Asia3 1 Nominal GDP at market exchange rates, Economist Intelligence Unit 2 IMS Prognosis 3 Economist Intelligence Unit; Euromonitor; S&P DRI; U.S. Department of Labor India12 Russia11 Brazil10 Spain9 Canada8 Italy7 France6 UK5 China4 Germany3 Japan2 US1 20062006GDP RankGDP Rank11 Brazil Italy Russia France UK India Germany Japan China US 20172017 Valid as of November 30, 2007
  17. 17. 17 Pfizer Well Positioned & Investing for Growth in Asia Strategic Highlights include: ● 2005: Opened Shanghai Research Center in China ● 2005–2007: Expanded clinical research activities with nearly 80 global studies ongoing & many more planned in all phases ● 2007: – Announced $300 million investment over next 5 years in South Korea R&D to develop drugs & medical technology alongside local research centers – Agreement reached to co-market with Novartis hypertension combination therapy Exforge in South Korea – Completed construction of first trigeneration power plant in Singapore to provide an environmental-friendly energy source for manufacturing processes Strategic Highlights include: ● 2005: Opened Shanghai Research Center in China ● 2005–2007: Expanded clinical research activities with nearly 80 global studies ongoing & many more planned in all phases ● 2007: – Announced $300 million investment over next 5 years in South Korea R&D to develop drugs & medical technology alongside local research centers – Agreement reached to co-market with Novartis hypertension combination therapy Exforge in South Korea – Completed construction of first trigeneration power plant in Singapore to provide an environmental-friendly energy source for manufacturing processes Pfizer Ranked #1 in Asia Pharma Market SalesPfizer Ranked #1 in Asia Pharma Market Sales for the 12 Month Period Ended 6/2007for the 12 Month Period Ended 6/2007(1)(1) (1) IMS Valid as of November 30, 2007
  18. 18. Martin Mackay President, Pfizer Global Research & Development November 30, 2007 Pfizer Research & Development Asia Investor Meeting Valid as of November 30, 2007
  19. 19. 19 R&D Five Point Plan Deliver the Phase II and Phase III Portfolio Prioritize our Portfolio to Deliver the Most Value Top-Tier Biotherapeutics Company Raise the Bar on Productivity Pursue Science Outside Our Walls Deliver the Phase II and Phase III Portfolio Prioritize our Portfolio to Deliver the Most Value Top-Tier Biotherapeutics Company Raise the Bar on Productivity Pursue Science Outside Our Walls Valid as of November 30, 2007
  20. 20. 20 R&D Footprint CambridgeCambridge TokyoTokyo ShanghaiShanghaiNew YorkNew York SingaporeSingapore St. LouisSt. Louis La JollaLa Jolla Groton/New LondonGroton/New London SandwichSandwich Biotherapeutic & Bioinnovation Center San Francisco Biotherapeutic & Bioinnovation Center San Francisco Valid as of November 30, 2007
  21. 21. 21 R&D Therapeutic Areas GERD Liver Fibrosis IBD GERD Liver Fibrosis IBD Gastrointestinal Indications Gastrointestinal Indications Infectious DiseaseInfectious Disease Bacterial Infections Fungal Infections HCV HIV Malaria Skin & Skin Structure Infections Bacterial Infections Fungal Infections HCV HIV Malaria Skin & Skin Structure Infections OncologyOncology Breast Cancer Colorectal Cancer Melanoma Lung Cancer Pancreatic Cancer Thyroid Neoplasm Other Cancers Breast Cancer Colorectal Cancer Melanoma Lung Cancer Pancreatic Cancer Thyroid Neoplasm Other Cancers OphthalmologyOphthalmology Age-Related Macular Degeneration Diabetic Macular Edema Glaucoma Age-Related Macular Degeneration Diabetic Macular Edema Glaucoma InflammationInflammation Osteoarthritis Rheumatoid Arthritis Transplant Rejection Osteoarthritis Rheumatoid Arthritis Transplant Rejection Alzheimer’s Disease Depression Epilepsy General Anxiety Disorder Insomnia Bipolar Disorder, Manic Depressive Illness Panic Disorder Schizophrenia Smoking Cessation Alzheimer’s Disease Depression Epilepsy General Anxiety Disorder Insomnia Bipolar Disorder, Manic Depressive Illness Panic Disorder Schizophrenia Smoking Cessation NeuroscienceNeuroscience Asthma COPD Asthma COPD Allergy/ Respiratory Allergy/ Respiratory Sexual Health Hot Flashes Lower Urinary Track Symptoms Incontinence Overactive Bladder Stress Incontinence Mixed Incontinence Sexual Health Hot Flashes Lower Urinary Track Symptoms Incontinence Overactive Bladder Stress Incontinence Mixed Incontinence Genitourinary/ Sexual Health Genitourinary/ Sexual Health Cardiovascular/ Metabolic Disease Cardiovascular/ Metabolic Disease Atherosclerosis Thrombosis Bone Healing Diabetes Hypertension Obesity Osteoporosis Short Stature/Growth Atherosclerosis Thrombosis Bone Healing Diabetes Hypertension Obesity Osteoporosis Short Stature/Growth DermatologyDermatology Alopecia Wrinkles Oily skin/Acne Skin Improvement Alopecia Wrinkles Oily skin/Acne Skin Improvement Acute Pain Chronic Pain Fibromyalgia Neuropathic Pain Osteoarthritic Pain Acute Pain Chronic Pain Fibromyalgia Neuropathic Pain Osteoarthritic Pain PainPain Valid as of November 30, 2007
  22. 22. 22 Global Reach & Unprecedented Scale ~400 projects in Discovery Research ~200 Development projects ~100 distinct new molecular entities Breadth and depth of pipeline across several Therapeutic Areas 12,000 R&D colleagues around the world 2006 R&D spend of $7.6B was the largest in the industry ~400 projects in Discovery Research ~200 Development projects ~100 distinct new molecular entities Breadth and depth of pipeline across several Therapeutic Areas 12,000 R&D colleagues around the world 2006 R&D spend of $7.6B was the largest in the industry Valid as of November 30, 2007
  23. 23. 23 Expanding the Scope A Leader in Innovation *Currently under development TherapyTherapyDiseaseDiseaseMechanismMechanism OncologyTyrosine Kinase Inhibition HIV/AIDSCCR-5 Antagonism Transplant Rejection, Rheumatoid Arthritis Janus Kinase 3 Inhibition Smoking CessationNicotine Partial Agonism Epilepsy, Neuropathic Pain, Anxiety, Sleep Disorders, Fibromyalgia Alpha 2 Delta Blockade Erectile Dysfunction, Pulmonary Hypertension PDE-5 Inhibition Pain & InflammationSelective COX-2 Inhibition CP-690,550* Valid as of November 30, 2007
  24. 24. 24 Oncology Leader Phase 1Phase 1 Phase 3Phase 3 Phase 2Phase 2 PreclinicalPreclinical MarketMarket Angiogenesis InhibitorsAngiogenesis Inhibitors Signal Transduction InhibitorsSignal Transduction Inhibitors Novel Cytotoxic AgentNovel Cytotoxic Agent Signal Transduction InhibitorsSignal Transduction Inhibitors Irreversible Pan-HER InhibitorIrreversible Pan-HER Inhibitor Angiogenesis InhibitorsAngiogenesis Inhibitors CD40 mAbCD40 mAb Chk1 InhibitorChk1 InhibitorC-Met InhibitorC-Met Inhibitor PARP InhibitorPARP Inhibitor Multi-RTK InhibitorMulti-RTK Inhibitor Anti-IGF-1R mAbAnti-IGF-1R mAb Anti - CTLA4 mAbAnti - CTLA4 mAb VEGFR InhibitorVEGFR Inhibitor MTK InhibitorMTK Inhibitor Discovery: >30 Individual Targets Undergoing InvestigationDiscovery: >30 Individual Targets Undergoing Investigation CDK4 InhibitorCDK4 Inhibitor TLR-9TLR-9 Valid as of November 30, 2007
  25. 25. 25 SutentSutent AxitinibAxitinib CPCP--675206675206 NSCLC, Breast, and Colorectal NSCLC, Breast, and Colorectal Thyroid and Pancreatic Cancer Thyroid and Pancreatic Cancer MelanomaMelanoma Multiple Tyrosine Kinase Inhibitor Multiple Tyrosine Kinase Inhibitor VEGFR Tyrosine Kinase Inhibitor VEGFR Tyrosine Kinase Inhibitor CTLA4 Receptor Antagonist CTLA4 Receptor Antagonist Phase 3 Programs Building Momentum in Oncology CompoundCompound IndicationsIndications MechanismMechanism Valid as of November 30, 2007
  26. 26. 26 Examples of Our Rich Portfolio of Phase 2 Candidates CP-690550 CP-751871 PF-4383119 PF-3187207 PD-200390 CP-690550 CP-751871 PF-4383119 PF-3187207 PD-200390 RA and Transplant Lung Cancer, Genitourinary, and Breast Cancer Pain Glaucoma Insomnia RA and Transplant Lung Cancer, Genitourinary, and Breast Cancer Pain Glaucoma Insomnia CompoundCompound IndicationsIndications Valid as of November 30, 2007
  27. 27. 27 Expanding the Scope of R&D (interferon beta-1a) (dalteparin sodium injection) (pegvisomant for injection) MCSF mAbMCSF mAb MAdCAM mAbMAdCAM mAb IGF1R mAbIGF1R mAb PEG-hGHPEG-hGH CD40 mAbCD40 mAb CTLA4 mAbCTLA4 mAb ETC-216ETC-216 St. Louis Biotherapeutics Center of ExcellenceSt. Louis Biotherapeutics Center of Excellence Staffed with ~250 ExpertsStaffed with ~250 Experts RN624RN624 RN1219RN1219 San Francisco Biotherapeutics & BioInnovation Center of ExcellenSan Francisco Biotherapeutics & BioInnovation Center of Excellencece Staffed with >100 ExpertsStaffed with >100 Experts Increasing Our Focus in BiotherapeuticsIncreasing Our Focus in Biotherapeutics Valid as of November 30, 2007
  28. 28. 28 Expanding Science Outside Our Walls Biotherapeutics & Bioinnovation Center Bristol-Myers Squibb ● Apixiban ● WW collaboration to research, develop and commercialize DGAT-1 inhibitors Scripps Research Institute ● Advance scientific knowledge of uncured diseases and novel ways to treat them Pfizer External Research Network – The Pfizer Incubator ● Gain rapid, broader access to science underlying disease and to enabling technologies Foundation for National Institutes of Health ● GAIN (Genetic Association Information Network) program Biotherapeutics & Bioinnovation Center Bristol-Myers Squibb ● Apixiban ● WW collaboration to research, develop and commercialize DGAT-1 inhibitors Scripps Research Institute ● Advance scientific knowledge of uncured diseases and novel ways to treat them Pfizer External Research Network – The Pfizer Incubator ● Gain rapid, broader access to science underlying disease and to enabling technologies Foundation for National Institutes of Health ● GAIN (Genetic Association Information Network) program Valid as of November 30, 2007
  29. 29. 29 China R&D Center (CRDC) Newest R&D facility Located in the renowned Zhangjiang High Tech Park, Shanghai, China Support Pfizer’s growth in China and other Asian countries through close alignment across Research, Development & Commercial Newest R&D facility Located in the renowned Zhangjiang High Tech Park, Shanghai, China Support Pfizer’s growth in China and other Asian countries through close alignment across Research, Development & Commercial Valid as of November 30, 2007
  30. 30. 30 Clinical Research Unit – Singapore One of three Pfizer Phase 1 Units Relocated to state-of-the-art facility in Raffles Hospital – June 2007 ● 3,000 square meters – largest clinical research facility ● Participates in many global programs ● 54 volunteer beds ● Staff of 70 Harmonized to Global SOPs/Guidance Ability to relay real-time data to Pfizer labs around the world One of three Pfizer Phase 1 Units Relocated to state-of-the-art facility in Raffles Hospital – June 2007 ● 3,000 square meters – largest clinical research facility ● Participates in many global programs ● 54 volunteer beds ● Staff of 70 Harmonized to Global SOPs/Guidance Ability to relay real-time data to Pfizer labs around the world Valid as of November 30, 2007
  31. 31. 31 DJ (Development Japan), Tokyo Full capacity development organization Co-located with Pfizer Japan Headquarters 385 staff including clinical, development operations, regulatory, CMC Organized for maximum synergy with global programs to support simultaneous approvals Full capacity development organization Co-located with Pfizer Japan Headquarters 385 staff including clinical, development operations, regulatory, CMC Organized for maximum synergy with global programs to support simultaneous approvals Valid as of November 30, 2007
  32. 32. 32 Five Point Plan Deliver the Phase II and Phase III Portfolio Prioritize our Portfolio to Deliver the Most Value Top-Tier Biotherapeutics Company Raise the Bar on Productivity Pursue Science Outside Our Walls Deliver the Phase II and Phase III Portfolio Prioritize our Portfolio to Deliver the Most Value Top-Tier Biotherapeutics Company Raise the Bar on Productivity Pursue Science Outside Our Walls Valid as of November 30, 2007
  33. 33. Q&A Session Asia Investor Meeting Valid as of November 30, 2007

×